Abstract
Rivaroxaban represents a selective direct inhibitor of activated coagulation factor X (FXa) having peroral bioavailability and prompt onset of action. The absorbtion of rivaroxaban is quick, reaching maximum plasma concentration 2-4 hours following its administration. Peroral bioavailability is high (80-100 %) and pharmacokinetic variability is considered to be moderate (coefficient of variation 30-40 %). This review discusses the properties, drug interactions, pharmacokinetics and clinical indications of rivaroxaban. Dosing regimen of rivaroxaban was derived from pharmacologic data of the development program aimed to gain strong antithrombotic drug and balance between efficacy and risk of bleeding in patients. Results of doseranging trials, pharmacokinetic models and randomised studies of phase III advocate the use of such schemes in everyday practice. The drug has been manufactured to fulfill clinical requirements in a variety of indications in adults: prophylaxis of venous thromboembolism (VTE) following elective knee or hip replacement surgical intervention, therapy and secondary prophylaxis of VTE, prophylaxis of ischemic stroke and embolism in individuals diagnosed with nonvalvular atrial fibrillation (NVAF) with risky ch...Continue Reading
Citations
Jul 19, 2019·Clinical Cardiology·Kaja AblefoniAndreas Bollmann
Jul 8, 2020·Pharmaceutical Biology·Jia ChongJiefu Yang
Aug 9, 2020·Platelets·Styliani PapadakiAlexandros D Tselepis
Jul 22, 2019·Pediatric Cardiology·Ján MiklerMarián Mokáň
Dec 31, 2019·Journal of Diabetes Research·Dana PrídavkováMarián Mokáň
Dec 26, 2018·Frontiers in Neurology·Alessandro GalganiEmilio Russo
May 27, 2020·Clinical and Applied Thrombosis/hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·Huimin HouHuiying Zhao
Nov 5, 2020·Critical Reviews in Analytical Chemistry·Tuba ReçberMustafa Çelebier
Dec 6, 2020·Clinical Pharmacology and Therapeutics·Nita A LimdiJeffry Florian
Jan 3, 2021·Thrombosis Research·Hongrui MaXunming Ji
Oct 30, 2020·Clinical Epidemiology·Marie LinderJulius Collin
Apr 4, 2021·Journal of Personalized Medicine·Silvia FernandezVictoria Rollason
May 14, 2021·Pharmacology Research & Perspectives·Ingrid ŠkorňováMarián Mokáň
May 15, 2021·Drug Design, Development and Therapy·Xiaoye LiQianzhou Lv
Jun 29, 2021·JRSM Open·Yan ZhuangMing-Qi Chen
Jul 2, 2021·Dermatologic Therapy·Yimeng Gao, Hongzhong Jin
Jul 16, 2021·Journal of Endodontics·Anita AminoshariaeDale Baur
Dec 19, 2020·Seizure : the Journal of the British Epilepsy Association·Charlotte Lawthom